Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
IntroductionWe evaluated the 3-year impact of adalimumab on patient-reported physical function and health-related quality-of-life (HRQOL) outcomes in patients with active ankylosing spondylitis (AS).
Methods: The Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS) is an ongoing 5-year study that included an initial 24-week, randomized, placebo-controlled, double-blind period, followed by open-label extension treatment with adalimumab. Clinical and HRQOL data collected for up to 3 years from ATLAS were used for these analyses.
Patients were randomized to receive adalimumab 40 mg or placebo by subcutaneous injection every other week. Physical function was assessed by the Bath AS Functional Index (BASFI), as well as by the Short Form 36 (SF-36) Health Survey Physical Component Summary (PCS) and Physical Function subscale scores.
HRQOL was assessed using the AS Quality of Life (ASQOL) questionnaire. Disease activity was assessed by the Bath AS Disease Activity Index (BASDAI).
Results: Of 315 patients enrolled in ATLAS, 288 (91%) participated in an open-label adalimumab treatment extension and 82% provided 3-year outcome data.
During the 24-week double-blind phase, adalimumab-treated patients experienced significant improvement compared with placebo-treated patients in the BASDAI (P <0.001), BASFI (P <0.001), ASQOL (P <0.001), and both the SF-36 PCS (P <0.001) and Physical Function subscale (P <0.001) scores, but not the SF-36 Mental Component Summary score (P = 0.181) and Mental Health subscale scores (P = 0.551). Mean changes from baseline through 3 years of adalimumab treatment were statistically significant for the BASDAI (change score: -3.9, P <0.001), BASFI (change score: -29.6, P <0.001), SF-36 PCS (change score: 11.6, P <0.001), and Physical Function (change score: 23.3, P <0.001).
Comparable results were observed for the other SF-36 scores and for the ASQOL (all P <0.001).
Conclusions: Adalimumab significantly improved disease activity, patient-reported physical function, and HRQOL. These benefits were maintained over 3 years of treatment in patients with AS.Trial registration: ClinicalTrials.gov NCT00085644
Author: Desiree van der HeijdeDennis RevickiKatherine GoochRobert WongHartmut KupperNeesha HarnamChris ThompsonJoachim SieperThe ATLAS Study Group
Credits/Source: Arthritis Research &Therapy 2009, 11:R124
Published on: 2009-08-17
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
